Author/Authors :
Hingorani، نويسنده , , Sunil R and Tuveson، نويسنده , , David A، نويسنده ,
Abstract :
Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy. The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emergence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.
